Based on its current operating plan, Arvinas believes its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2023, is sufficient to fund planned operating expenses and capital expenditure requirements into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARVN:
- Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Arvinas & Pfizer win UK Innovation award in UK for Vepdegestrant
- Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
- Pfizer, Arvinas and Carrick Therapeutics collaborate for oncological combination
- Goldman Sachs Says Attractive Valuations Make Small-Cap Stocks Appealing; Here Are 2 ‘Strong Buy’ Names With Solid Upside Potential